|
1
|
Al Knawy B and Shiffman M: Percutaneous
liver biopsy in clinical practice. Liver Int. 27:1166–1173. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ratziu V, Charlotte F, Heurtier A, Gombert
S, Giral P, Bruckert E, Grimaldi A, Capron F and Poynard T; LIDO
Study Group, : Sampling variability of liver biopsy in nonalcoholic
fatty liver disease. Gastroenterology. 128:1898–1906. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McPherson S, Stewart SF, Henderson E, Burt
AD and Day CP: Simple non-invasive fibrosis scoring systems can
reliably exclude advanced fibrosis in patients with non-alcoholic
fatty liver disease. Gut. 59:1265–1269. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Angulo P, Bugianesi E, Bjornsson ES,
Charatcharoenwitthaya P, Mills PR, Barrera F, Haflidadottir S, Day
CP and George J: Simple noninvasive systems predict long-term
outcomes of patients with nonalcoholic fatty liver disease.
Gastroenterology. 145:782–789.e4. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yoneda M, Imajo K, Eguchi Y, Fujii H,
Sumida Y, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Aoki N, et al:
Noninvasive scoring systems in patients with nonalcoholic fatty
liver disease with normal alanine aminotransferase levels. J
Gastroenterol. 48:1051–1060. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Minami H, Sai K, Saeki M, Saito Y, Ozawa
S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, et al:
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic
polymorphisms in Japanese: Roles of UGT1A1*6 and *28. Pharmacogenet
Genomics. 17:497–504. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cancer Therapy Evaluation Program (CTEP),
. N.C.I. Adverse Events (CTCAE) Version 4.0. 2009 June 14, 2010
[cited 2009 May 28]. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
|
|
8
|
Klein CE, Gupta E, Reid JM, Atherton PJ,
Sloan JA, Pitot HC, Ratain MJ and Kastrissios H: Population
pharmacokinetic model for irinotecan and two of its metabolites,
SN-38 and SN-38 glucuronide. Clin Pharmacol Ther. 72:638–647. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Iyer L, King CD, Whitington PF, Green MD,
Roy SK, Tephly TR, Coffman BL and Ratain MJ: Genetic predisposition
to the metabolism of irinotecan (CPT-11). Role of uridine
diphosphate glucuronosyltransferase isoform 1A1 in the
glucuronidation of its active metabolite (SN-38) in human liver
microsomes. J Clin Invest. 101:847–854. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hirose K, Kozu C, Yamashita K, Maruo E,
Kitamura M, Hasegawa J, Omoda K, Murakami T and Maeda Y:
Correlation between plasma concentration ratios of SN-38
glucuronide and SN-38 and neutropenia induction in patients with
colorectal cancer and wild-type UGT1A1 gene. Oncol Lett. 3:694–698.
2012.PubMed/NCBI
|
|
11
|
Innocenti F, Undevia SD, Iyer L, Chen PX,
Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM,
et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene
predict the risk of severe neutropenia of irinotecan. J Clin Oncol.
22:1382–1388. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Onoue M, Terada T, Kobayashi M, Katsura T,
Matsumoto S, Yanagihara K, Nishimura T, Kanai M, Teramukai S,
Shimizu A, et al: UGT1A1*6 polymorphism is most predictive of
severe neutropenia induced by irinotecan in Japanese cancer
patients. Int J Clin Oncol. 14:136–142. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ramchandani RP, Wang Y, Booth BP, Ibrahim
A, Johnson JR, Rahman A, Mehta M, Innocenti F, Ratain MJ and
Gobburu JV: The role of SN-38 exposure, UGT1A1*28 polymorphism, and
baseline bilirubin level in predicting severe irinotecan toxicity.
J Clin Pharmacol. 47:78–86. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sai K, Saeki M, Saito Y, Ozawa S, Katori
N, Jinno H, Hasegawa R, Kaniwa N, Sawada J, Komamura K, et al:
UGT1A1 haplotypes associated with reduced glucuronidation and
increased serum bilirubin in irinotecan-administered Japanese
patients with cancer. Clin Pharmacol Ther. 75:501–515. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bosma PJ, Saeki M, Saito Y, Ozawa S,
Katori N, Jinno H, Hasegawa R, Kaniwa N, Sawada J and Komamura K:
Bilirubin UDP-glucuronosyltransferase 1 is the only relevant
bilirubin glucuronidating isoform in man. J Biol Chem.
269:17960–17964. 1994.PubMed/NCBI
|
|
16
|
Meyerhardt JA, Kwok A, Ratain MJ, McGovren
JP and Fuchs CS: Relationship of baseline serum bilirubin to
efficacy and toxicity of single-agent irinotecan in patients with
metastatic colorectal cancer. J Clin Oncol. 22:1439–1446. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Raymond E, Boige V, Faivre S, Sanderink
GJ, Rixe O, Vernillet L, Jacques C, Gatineau M, Ducreux M and
Armand JP: Dosage adjustment and pharmacokinetic profile of
irinotecan in cancer patients with hepatic dysfunction. J Clin
Oncol. 20:4303–4312. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hao H, Zhang L, Jiang S, Sun S, Gong P,
Xie Y, Zhou X and Wang G: Thioacetamide intoxication triggers
transcriptional up-regulation but enzyme inactivation of
UDP-glucuronosyltransferases. Drug Metab Dispos. 39:1815–1822.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xie Y, Wang G, Wang H, Yao X, Jiang S,
Kang A, Zhou F, Xie T and Hao H: Cytochrome P450 dysregulations in
thioacetamide-induced liver cirrhosis in rats and the counteracting
effects of hepatoprotective agents. Drug Metab Dispos. 40:796–802.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ikuno N, Soda H, Watanabe M and Oka M:
Irinotecan (CPT-11) and characteristic mucosal changes in the mouse
ileum and cecum. J Natl Cancer Inst. 87:1876–1883. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Takasuna K, Hagiwara T, Hirohashi M, Kato
M, Nomura M, Nagai E, Yokoi T and Kamataki T: Involvement of
beta-glucuronidase in intestinal microflora in the intestinal
toxicity of the antitumor camptothecin derivative irinotecan
hydrochloride (CPT-11) in rats. Cancer Res. 56:3752–3757.
1996.PubMed/NCBI
|
|
22
|
Li M, Wang Z, Guo J, Liu J, Li C, Liu L,
Shi H, Liu L, Li H, Xie C, et al: Clinical significance of UGT1A1
gene polymorphisms on irinotecan-based regimens as the treatment in
metastatic colorectal cancer. Onco Targets Ther. 7:1653–1661.
2014.PubMed/NCBI
|
|
23
|
Rambach L, Bertaut A, Vincent J, Lorgis V,
Ladoire S and Ghiringhelli F: Prognostic value of
chemotherapy-induced hematological toxicity in metastatic
colorectal cancer patients. World J Gastroenterol. 20:1565–1573.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shitara K, Matsuo K, Takahari D, Yokota T,
Inaba Y, Yamaura H, Sato Y, Najima M, Ura T and Muro K:
Neutropaenia as a prognostic factor in metastatic colorectal cancer
patients undergoing chemotherapy with first-line FOLFOX. Eur J
Cancer. 45:1757–1763. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu CY, Chen PM, Chiou TJ, Liu JH, Lin JK,
Lin TC, Chen WS, Jiang JK, Wang HS and Wang WS: UGT1A1*28
polymorphism predicts irinotecan-induced severe toxicities without
affecting treatment outcome and survival in patients with
metastatic colorectal carcinoma. Cancer. 112:1932–1940. 2008.
View Article : Google Scholar : PubMed/NCBI
|
